Research on pain management, the treatment gap, and cellular therapy
Research on pain management, the treatment gap, and cellular therapy There is much to discover about how cell therapy has the potential to close the treatment gap between pain management and major surgery. Our research on OA of the knee, part of a pivotal Phase III trial, makes this trial one of those farthest […]
GID BIO CEO William Cimino moderates panel at recent IFATS conference
Bill Cimino, Ph.D. GID BIO CEO William Cimino, Ph.D., moderated […]
New trial site, the University of Pittsburgh Medical Center, joins GID BIO’s pivotal Phase III trial
Peter Rubin, MD, MBA, FACS, Endowed Professor and Chair of Plastic Surgery at the Center for Innovation in Restorative Medicine at UPMC and the University of Pittsburgh joins as GID BIO’s latest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis. “This […]
AdventHealth Orlando joins as newest trial site in pivotal Phase III trial
Tariq Awan, DO, a double-certified family and sports medicine physician with a special focus in sports medicine enters as GID BIO’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis. He has served as team physician for the […]
Cell Therapy to Address Treatment Gap Between Pain Management and End-stage Surgery for Chronic Degenerative Diseases
To download the white paper click below: […]
Wake Forest Medical School added as newest site in pivotal Phase III trial
Neil Sparks, DO, MS, a North Carolina physician specializing in the comprehensive primary and musculoskeletal care of children, adults and families, is the newest principal investigator in GID BIO’s pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis.Dr. Sparks leads a team of three, […]
UC Davis joins as trial site in pivotal Phase III trial
Charles De Mesa, DO, MPH, a Northern California practicing specialist in anesthesiology and pain medicine, physical medicine and rehabilitation and musculoskeletal pain medicine is GID Bio’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis. Dr. De Mesa leads a […]
OrthoCarolina joins as trial site in pivotal Phase III trial
OrthoCarolina, GID BIO’s newest Phase III trial site, is led by Dr. Claude T. Moorman III as principal investigator. Dr. Moorman is a sports medicine surgeon at OrthoCarolina’s Sports Medicine Center; the president of Atrium Health’s Musculoskeletal Institute; and Chair of Atrium Health’s Department of Orthopaedic Surgery. He has experience treating NFL, collegiate and high […]
<i>Orlando Medical News</i> features GID BIO and pivotal/Phase III trial
<i>San Antonio Business Journal</i> features GID BIO and pivotal/Phase III trial principal investigator, Dr. Jaime Garza: “On the forefront of new cell therapy research, an Alamo City surgeon has a key role in moving new medical technology to market”
GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results… Read more via ORTHOWORLD: https://www.orthoworld.com/index.php/publications/orthoflash/gid-bio-completes-trial-of-stromal-cells-to-treat-knee-oa
